$308.32
0.76% today
Nasdaq, May 20, 08:15 pm CET
ISIN
US58506Q1094
Symbol
MEDP

Medpace Stock price

$305.98
+16.99 5.88% 1M
-8.98 2.85% 6M
-26.25 7.90% YTD
-91.27 22.98% 1Y
+172.18 128.68% 3Y
+219.54 253.98% 5Y
+278.19 1,001.04% 10Y
Nasdaq, Closing price Mon, May 19 2025
+0.32 0.10%
ISIN
US58506Q1094
Symbol
MEDP
Sector
Industry

Key metrics

Market capitalization $8.79b
Enterprise Value $8.50b
P/E (TTM) P/E ratio 23.35
EV/FCF (TTM) EV/FCF 15.72
EV/Sales (TTM) EV/Sales 3.94
P/S ratio (TTM) P/S ratio 4.08
P/B ratio (TTM) P/B ratio 15.34
Revenue growth (TTM) Revenue growth 9.87%
Revenue (TTM) Revenue $2.16b
EBIT (operating result TTM) EBIT $456.32m
Free Cash Flow (TTM) Free Cash Flow $540.93m
Cash position $441.44m
EPS (TTM) EPS $13.10
P/E forward 23.96
P/S forward 4.03
EV/Sales forward 3.89
Short interest 11.69%
Show more

Is Medpace a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Medpace Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Medpace forecast:

2x Buy
17%
10x Hold
83%

Analyst Opinions

12 Analysts have issued a Medpace forecast:

Buy
17%
Hold
83%

Financial data from Medpace

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,157 2,157
10% 10%
100%
- Direct Costs 1,506 1,506
5% 5%
70%
650 650
25% 25%
30%
- Selling and Administrative Expenses 165 165
22% 22%
8%
- Research and Development Expense - -
-
-
486 486
25% 25%
23%
- Depreciation and Amortization 29 29
10% 10%
1%
EBIT (Operating Income) EBIT 456 456
29% 29%
21%
Net Profit 416 416
33% 33%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Medpace directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Medpace Stock News

Neutral
Seeking Alpha
28 days ago
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Ann Hynes - Mizuho Dan Leonard - UBS Eric Coldwe...
Negative
Investors Business Daily
28 days ago
Medpace stock tumbled Tuesday after lighter-than-expected bookings in the March quarter "cast more doubt on the path forward."
Neutral
Business Wire
29 days ago
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue for the three months ended March 31, 2025 increased 9.3% to $558.6 million, compared to $511.0 million for the comparable prior-year period. On a constant currency basis, revenue for the first qu...
More Medpace News

Company Profile

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.

Head office United States
CEO August Troendle
Employees 5,900
Founded 1992
Website www.medpace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today